TIDMCIR

RNS Number : 0341K

Circassia Pharmaceuticals Plc

10 December 2018

CIRCASSIA PHARMACEUTICALS PLC

POSTING OF SHAREHOLDER CIRCULAR

Oxford, UK - 10 December 2018: Circassia Pharmaceuticals plc ("Circassia" or "the Company") (LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that further to the announcement earlier today, a Circular has been published and will be posted to shareholders today in relation to the proposed cancellation of ordinary shares from the Official List and Admission to trading on AIM. The Circular contains the notice convening the General Meeting to be held at the offices of Circassia Pharmaceuticals plc, Northbrook House, Robert Robinson Avenue, The Oxford Science Park, Oxford, Oxfordshire, OX4 4GA, United Kingdom at 12 midday on 4 January 2019.

A copy of the Circular will shortly be available on the Company's website at www.circassia.com.

Enquiries

 
 Circassia 
 Steve Harris, Chief Executive Officer   Tel: +44 (0) 1865 405 560 
 Julien Cotta, Chief Financial Officer 
 Rob Budge, Corporate Communications 
 
 Peel Hunt 
 James Steel / Dr. Christopher Golden    Tel: +44 (0) 20 7418 8900 
 
 Numis Securities 
 James Black / Freddie Barnfield         Tel: +44 (0) 20 7260 1000 
 
 FTI Consulting 
 Simon Conway / Mo Noonan                Tel: +44 (0) 20 3727 1000

About Circassia

Circassia is a world-class specialty pharmaceutical business focused on respiratory disease. Circassia sells its novel, market-leading NIOX(R) asthma management products directly to specialists in the United States, United Kingdom and Germany, and in a wide range of other countries through its network of partners. In 2017, the Company established a commercial collaboration with AstraZeneca in the United States in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza(R) and has the commercial rights to NDA-stage COPD product Duaklir(R). For more information please visit www.circassia.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

CIRURVBRWSAUAAA

(END) Dow Jones Newswires

December 10, 2018 12:59 ET (17:59 GMT)

Circassia (LSE:CIR)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Circassia Charts.
Circassia (LSE:CIR)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Circassia Charts.